A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra‐cranial solid tumors: A Children's Oncology Group Phase I Consortium report

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pediatric Blood & Cancer

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.25464PMID 25728527PMCID PMC4376570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.

  2014influential reference
• Cytotoxic and immune‐mediated killing of human colorectal cancer by reovirus‐loaded blood and liver mononuclear cells

  2013cited by this paper
• REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

  2013cited by this paper
• Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma

  2012cited by this paper
• Clinical trials involving the oncolytic virus, reovirus: ready for prime time?

  2012cited by this paper
• Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.

  2012cited by this paper
• Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

  2012cited by this paper
• Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer

  2012cited by this paper
• Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts

  2011cited by this paper
• Novel Human Reovirus Isolated from Children with Acute Necrotizing Encephalopathy

  2011cited by this paper
• REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

  2010cited by this paper
• Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

  2010cited by this paper
• A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

  2010influential reference
• Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Reovirus-based therapy for cancer

  2009cited by this paper
• A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

  2008cited by this paper
• Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

  2008cited by this paper
• A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

  2008cited by this paper
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

  2007cited by this paper
• Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.

  2007cited by this paper
• Immunosuppression promotes reovirus therapy of colorectal liver metastases

  2006cited by this paper
• Prevalence of Reovirus-Specific Antibodies in Young Children in Nashville, Tennessee

  2005cited by this paper
• Pediatr Blood Cancer

  2004cited by this paper
• Reovirus therapy of tumors with activated Ras pathway.

  1998cited by this paper
• The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

  1998influential reference
• Proteolytic digestion of reovirus in the intestinal lumens of neonatal mice

  1989cited by this paper
• Lack of correlation between infection with reovirus 3 and extrahepatic biliary atresia or neonatal hepatitis.

  1988cited by this paper
• Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis.

  1987cited by this paper
• Adherence to and penetration of the intestinal epithelium by reovirus type 1 in neonatal mice.

  1987cited by this paper
• Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease

  1985cited by this paper
• The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease

  1985cited by this paper
• Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine.

  1983cited by this paper
• The sigma 1 protein determines the extent of spread of reovirus from the gastrointestinal tract of mice.

  1983cited by this paper
• Comparative Diagnosis of Viral Diseases

  1982cited by this paper
• Viruses causing common respiratory infections in man. V. influenza A (Asian).

  1975cited by this paper
• Viruses causing common respiratory infections in man.

  1973cited by this paper
• Reovirus type 3 associated with fatal pneumonia.

  1967cited by this paper
• Reovirus infections in human volunteers.

  1963cited by this paper
• Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described.

  1959cited by this paper

• Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors

  2026cites this paper
• A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy

  2026cites this paper
• Directed evolution generates an oncolytic Sindbis virus with enhanced tumor-killing capacity in osteosarcoma

  2025cites this paper
• Reovirus oncolysis and the next frontiers for this unique oncoviral immunotherapy.

  2025cites this paper
• Mesenchymal stem cell-derived small extracellular vesicles as a delivery vehicle of oncolytic reovirus.

  2025cites this paper
• Emergent and underexplored oncolytic viruses for treating pediatric central nervous system tumors

  2024cites this paper
• Oncolytic Viral Therapy in Osteosarcoma

  2024cites this paper
• Translation of oncolytic viruses in sarcoma

  2024cites this paper
• Progress of Oncolytic Virus

  2024cites this paper
• The Emerging Field of Viroimmunotherapy for Pediatric Brain Tumors.

  2024cites this paper
• "Innovations in Cancer Immunotherapy: A Comprehensive Overview of Recent Breakthroughs and Future Directions".

  2024cites this paper
• Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.

  2023cites this paper
• Oncolytic virotherapies for pediatric tumors

  2023cites this paper
• Anticancer Activity of Measles–Mumps–Rubella MMR Vaccine Viruses against Glioblastoma

  2023cites this paper
• Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?

  2023cites this paper
• Development and application of oncolytic viruses as the nemesis of tumor cells

  2023cites this paper
• Vaccinating against cancer: getting to prime time

  2023cites this paper
• A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors

  2023cites this paper
• Oncolytic virotherapy: basic principles, recent advances and future directions

  2023cites this paper
• Therapy with oncolytic viruses: progress and challenges

  2023cites this paper
• Clinical advances in oncolytic virotherapy for pediatric brain tumors.

  2022cites this paper
• Review: Neurological Complications From Therapies for Pediatric Brain Tumors

  2022cites this paper
• Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality

  2022cites this paper
• Pteropine Orthoreovirus, PRV7S (Sikamat Virus) Demonstrates Oncolysis in Nasopharyngeal Carcinoma Cell Lines.

  2022cites this paper
• Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma

  2022cites this paper
• Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML

  2022influential citation
• Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors

  2022cites this paper
• Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical

  2022cites this paper
• Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults

  2022influential citation
• The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma

  2021cites this paper
• A systematic analysis on the clinical safety and efficacy of onco-virotherapy

  2021cites this paper
• MSCs loaded with oncolytic reovirus: migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL/6 mice

  2021cites this paper
• Current strategies of virotherapy in clinical trials for cancer treatment

  2021cites this paper
• Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis

  2021cites this paper
• Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy

  2021cites this paper
• Sarcomas of Bone and Soft Tissues in Children and Adolescents

  2021cites this paper
• Mesenchymal stem cell carriers enhance antitumor efficacy induced by oncolytic reovirus in acute myeloid leukemia.

  2021cites this paper
• Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements

  2021cites this paper
• Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma

  2021cites this paper
• Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure–response analysis of pomalidomide

  2021cites this paper
• Immunotherapy for Pediatric Sarcomas

  2020cites this paper
• Oncolytic viruses: what to expect from their use in cancer treatment

  2020cites this paper
• Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.

  2020cites this paper
• First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors.

  2020cites this paper
• Mini-Review on Targeted Treatment of Desmoplastic Small Round Cell Tumor

  2020cites this paper
• Review on Application of Oncolytic Virotherapy of Cancer Cells in Veterinary Medicine

  2020cites this paper
• First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

  2020cites this paper
• A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas

  2020cites this paper
• Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma.

  2020cites this paper
• Cytokine and Growth Factor Determinants of the efficacy of viro-immunotherapy: A review

  2020cites this paper
• Clinical landscape of oncolytic virus research in 2020

  2020cites this paper
• Sarcoma treatment in the era of molecular medicine

  2020cites this paper
• Clinical Application of Oncolytic Viruses: A Systematic Review

  2020cites this paper
• Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma

  2019cites this paper
• Immunotherapeutic Challenges for Pediatric Cancers

  2019cites this paper
• First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial

  2019cites this paper
• NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy

  2017cites this paper
• Investigating the role of programmed necrosis in oncolytic adenovirus-induced death

  2017cites this paper
• Review: Oncolytic virotherapy, updates and future directions

  2017cites this paper
• Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients

  2017cites this paper
• Review: Oncolytic Virotherapy, updates and future directions.

  2017cites this paper
• Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma

  2017cites this paper
• Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy

  2017cites this paper
• Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus

  2017cites this paper
• Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot

  2017cites this paper
• Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia

  2017influential citation
• Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro

  2017cites this paper
• Targeted immunotherapy for pediatric solid tumors

  2016cites this paper
• Oncolytic virotherapy for urological cancers

  2016cites this paper
• Enhancement of oncolytic herpes simplex type 1 virotherapy

  2016cites this paper
• Optimising Reovirus Type 3 Dearing (Reolysin®) as an anti-cancer therapeutic

  2016cites this paper
• Oncolytic viruses—immunotherapeutics on the rise

  2016cites this paper
• Oncolytic virotherapy for pediatric malignancies: future prospects

  2016cites this paper
• Trial Watch—Oncolytic viruses and cancer therapy

  2016cites this paper
• Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens

  2015cites this paper
• Attack of the cancer‐killing viruses: Clinical application of oncolytic virotherapy in children

  2015cites this paper
• EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

  2015cites this paper
• Novel Therapies on the Horizon

  2015cites this paper
• Trial Watch:

  2014cites this paper